A randomized cross over trial of tolerability and compliance of a micronutrient supplement with low iron separated from calcium vs high iron combined with calcium in pregnant women [ISRCTN56071145]

被引：21

作者：

Ahn E. ^{[2
]}

Pairaudeau N. ^{[2
]}

Cérat Y.

Couturier B.

Fortier A.

Paradis É.

Koren G. ^{[1
]}

机构：

[1] The University of Toronto, Clinique de Gynécologie-Obstétrique Pierre Boucher, Longueuil, Que.

[2] Division of Clinical Pharmacology/Toxicology, The Hospital for Sick Children, North York General Hospital, Toronto, Ont.

来源：

BMC Pregnancy and Childbirth | / 6卷 / 1期

关键词：

Neural Tube Defect; Compliance Rate; Pill Count; High Iron Content; Elemental Iron;

D O I：

10.1186/1471-2393-6-10

中图分类号：

学科分类号：

摘要：

Background: Prenatal micronutrient combinations with high iron content are associated with high rates of gastrointestinal symptoms. This coupled with nausea and vomiting of pregnancy results in women often discontinuing their multivitamins. A new prescription supplement (PregVit®) that separates iron from calcium in two tablets - morning and evening, has lower elemental iron content (35 mg), but results in similar extent of iron absorption when compared to another supplement containing (60 mg) of elemental iron (Materna®). The objectives of this study were to compare tolerability and compliance with PregVit® vs. a supplement with high iron content (Materna®), in pregnant women. Methods: Randomized, crossover open labeled study in 135 pregnant women attending outpatient clinics in Ontario and Quebec. Results: Use of PregVit® was associated with a 30% reduction in constipation rate as compared to Materna®. Both products demonstrated similar compliance rates. Compliance of Materna® was negatively associated with the severity of nausea and vomiting of pregnancy. No such correlation was found for PregVvit®. Conclusion: PregVit®, a supplement with lower iron content (35 mg), has significantly decreased constipation rates as compared to 60 mg iron- Materna and has similar compliance rates. High iron content in multivitamin supplements is associated with adverse effects in pregnancy. © 2006 Ahn et al; licensee BioMed Central Ltd.

引用

共 21 条

[1]

(1989)

[2]

Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Sillicon, Vanadium, and Zinc, pp. 770-773, (2002)

[3]

Czeizel A.E., Dudas I., Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation, N Engl J Med, 327, pp. 1832-1835, (1992)

[4]

Wald N., Hack Shaw A., Folic acid and prevention of neural-tube defects, Lancet, 350, (1992)

[5]

Botto L.D., Olney R.S., Erickson J.D., Vitamin supplements and the risk for congenital anomalies other than neural tube defects, Am J Med Genet, 125, pp. 12-21, (2004)

[6]

Botto L.D., Olney R.S., Erickson J.D., Vitamin supplements and the risk for congenital anomalies other than neural tube defects, Am J Med Genet C Semin Med Genet, 125, pp. 12-21, (2004)

[7]

Koren G., Piwko C., Ahn E., Boskovic R., Et al., Validation studies of the pregnancy unique quantification of emesis (PUQE) scores, J Obstet Gynecol

[8]

Bendich A., Calcium supplementation and iron status offemales, Nutr, 17, pp. 46-51, (2001)

[9]

Cook J.D., Dassenko S.A., Whittaker P., Calcium supplementation: Effect on iron absorption, Am J Clin Nutr, 53, pp. 106-111, (1991)

[10]

Zijp I.M., Koryer O., Tijburg L.B., Effect of tea and other dietary factors on iron absorption, Crit Rev Food Sci Nutr, 40, pp. 371-398, (2000)

← 1 2 3 →